Welcome to our dedicated page for Myomo SEC filings (Ticker: MYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Myomo Inc. filings document material events for a Delaware medical-device company focused on wearable robotics and the MyoPro powered upper-limb orthosis. Recent Form 8-K disclosures furnish quarterly and annual operating results, revenue sources, MyoPro orders and authorizations, patient-pipeline activity, and exhibits tied to financial press releases.
The filing record also covers governance and capital-structure matters, including board appointments, director compensation arrangements, indemnification agreements, and loan and security agreements. These disclosures describe formal reporting of operating performance, financing terms, corporate governance actions and related risk and control subjects for MYO.
Myomo, Inc. filed an amended current report to correct exhibit labels and hyperlinks in a prior 8-K, with no changes to the underlying actions. At the June 25, 2026 Annual Meeting, stockholders approved an amendment to the 2018 Stock Option and Incentive Plan, increasing shares available under the plan by 1,833,000.
Stockholders also approved a Charter Amendment increasing authorized common stock to 100,000,000 shares, which became effective upon filing with Delaware on June 25, 2026. As of April 29, 2026, 38,638,669 common shares were outstanding and entitled to vote. All proposals on the agenda, including director elections, executive compensation on an advisory basis, auditor ratification, a stockholder proposal on director classification, and the ability to adjourn the meeting, received the requisite support.
MYOMO, INC. director Joseph M. Manko Jr. reported an acquisition of 78,704 shares of Common Stock as a grant or award. The transaction was recorded at a price of $0.00 per share, and his direct holdings after the transaction total 78,704 shares.
A footnote states he elected to defer receipt of the common stock issuable upon vesting of the related RSUs until the earlier of 30 days after termination of service or a change in control.
Crowley Thomas Aloysius Jr. reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. director Thomas Aloysius Crowley Jr. received a grant of 78,704 Restricted Stock Units, each representing one share of common stock, at no cash cost. These RSUs vest in four equal quarterly installments beginning on September 9, 2026. Following this award, he directly holds 154,452 shares.
KIRK THOMAS F reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. director Kirk Thomas F reported receiving a grant of 78,704 Restricted Stock Units under the company’s 2018 Stock Option and Incentive Plan. Each unit represents a contingent right to one share of common stock.
The Restricted Stock Units vest in four equal quarterly installments beginning on September 9, 2026, meaning the director earns the shares over time rather than all at once. Following this grant, he reports beneficial ownership of 772,569 shares or units of common stock.
Getz Heather C reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. director Heather C. Getz reported a grant of 78,704 shares of Common Stock in the form of Restricted Stock Units under the company’s 2018 Stock Option and Incentive Plan. This was a compensation award, not an open-market purchase.
Each RSU represents a contingent right to receive one share of common stock and will vest in four quarterly installments beginning on September 9, 2026. Getz has elected to defer receipt of the underlying common shares until the earlier of 30 days after her service ends or a change in control. Following this grant, she directly holds 210,458 shares of common stock.
FEBBO WILLIAM J reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. director William J. Febbo reported an equity compensation grant of 78,704 shares of Common Stock in the form of Restricted Stock Units under the company’s 2018 Stock Option and Incentive Plan. The RSUs carry no cash purchase price and represent a contingent right to receive one share of common stock each.
The RSUs vest in four equal quarterly installments beginning on September 9, 2026. After this grant, Febbo directly holds a reported total of 123,704 shares of MYOMO common stock.
Morris Milton Mayo reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. director Morris Milton Mayo reported an award of 78,704 shares of common stock in the form of Restricted Stock Units under the company’s 2018 Stock Option and Incentive Plan. Following the grant, he directly holds 223,391 shares.
The RSUs vest in four equal quarterly installments beginning on September 9, 2026, with each unit representing a contingent right to receive one share of common stock. Mayo has elected to defer actual receipt of the common stock until the earlier of 30 days after his service ends or a change in control.
Myomo, Inc. reported results from its June 25, 2026 Annual Meeting of Stockholders, where several governance and capital structure changes were approved. Stockholders adopted an amendment to the company’s 2018 Stock Option and Incentive Plan, adding 1,833,000 shares available for equity awards.
They also approved a Charter Amendment increasing the authorized number of common shares to 100,000,000, which became effective upon filing in Delaware on June 25, 2026. As of April 29, 2026, 38,638,669 common shares were outstanding and entitled to vote.
Shareholders elected two Class III directors, approved an advisory vote on executive compensation, ratified CBIZ CPAs P.C. as auditor for 2026, supported a stockholder proposal on director classification, and authorized potential adjournments to solicit additional proxies if needed.
MYOMO, INC. Chief Medical Officer Harry Kovelman reported a Form 4 transaction where 10,442 shares of Common Stock were sold at $1.20 per share on June 12, 2026. According to the footnote, these shares were sold solely to pay income taxes from restricted stock units that vested on June 11, 2026, under an earlier irrevocable election. After this tax-withholding disposition, Kovelman directly owns 90,541 shares.
MYOMO, INC. Chief Commercial Officer Micah Mitchell reported a tax-related share disposition. On June 12, 2026, 9,061 shares of common stock at $1.20 per share were delivered to cover income taxes arising from restricted stock units that vested on June 11, 2026, under a prior irrevocable election. Following this transaction, he holds 93,888 shares of common stock directly.